Vor Biopharma
61 hedge funds and large institutions have $362M invested in Vor Biopharma in 2021 Q4 according to their latest regulatory filings, with 11 funds opening new positions, 20 increasing their positions, 14 reducing their positions, and 4 closing their positions.
175% more first-time investments, than exits
New positions opened: 11 | Existing positions closed: 4
43% more repeat investments, than reductions
Existing positions increased: 20 | Existing positions reduced: 14
43% more capital inflows, than outflows
Capital inflows: $25.7M | Capital outflows: $18.1M
11% more funds holding
Funds holding: 55 → 61 (+6)
0.93% more ownership
Funds ownership: 82.6% → 83.54% (+0.93%)
50% less funds holding in top 10
Funds holding in top 10: 4 → 2 (-2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$3.94M |
| 2 |
Laurion Capital Management
New York
|
+$2.88M |
| 3 |
Ameriprise
Minneapolis,
Minnesota
|
+$831K |
| 4 |
Ensign Peak Advisors
Salt Lake City,
Utah
|
+$583K |
| 5 |
Qube Research & Technologies (QRT)
London,
United Kingdom
|
+$430K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
-$5.03M |
| 2 |
5AM Venture Management
San Francisco,
California
|
-$4.77M |
| 3 |
Putnam Investments
Boston,
Massachusetts
|
-$3.74M |
| 4 |
Parametric Portfolio Associates
Seattle,
Washington
|
-$1.66M |
| 5 |
Gilder Gagnon Howe & Co
New York
|
-$678K |
VOR Hedge Fund Activity: Q4 2021 in Review
61 of the 6,522 institutional investors tracked by Wall St. Rank reported a position in Vor Biopharma (VOR) for Q4 2021, worth a combined $362M — down 25% from $481M a quarter earlier.
Buyers outnumbered sellers: 11 funds opened new VOR positions and 4 closed out — a net gain of 7 holders — while 20 added to existing stakes and 14 trimmed.
The largest buyer was BlackRock, adding an estimated $3.94M. The largest seller was Vanguard Group, cutting an estimated $5.03M.
- 61 institutional investors held Vor Biopharma (VOR) as of Q4 2021, up from 55 in Q3 2021.
- Funds reported $362M of Vor Biopharma stock for Q4 2021, down 25% quarter-over-quarter.
- 11 funds opened new Vor Biopharma positions in Q4 2021 and 4 closed out, a net change of +7 holders.
- The largest Vor Biopharma buyer in Q4 2021 was BlackRock, an estimated $3.94M added.
- The largest Vor Biopharma seller in Q4 2021 was Vanguard Group, an estimated $5.03M sold.
Based on aggregated 13F filings for Q4 2021.